Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | NOS2 | P35228 | 4/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818474 | 1.00 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EMEN1 | |
| Bicarbonate SCHEMBL5997835 | 0.90 | KDM4E (0.61) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL4665680 | 0.78 | NOS3 (0.44) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL2235251 | 0.77 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EMEN1 | |
| 2-Aminopyridine SCHEMBL9487893 | 0.77 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL196641 | 0.76 | ALDH1A1 (0.53) | KDM4EMEN1KMT2AALDH1A1CHRM5 | |
| SCHEMBL16212184 | 0.75 | NOS2 (0.42) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL1857798 | 0.74 | UHRF1 (0.52) | KDM4EALDH1A1CHRM5CHKAALOX15 | |
| SCHEMBL30002302 | 0.74 | UHRF1 (0.52) | KDM4EALDH1A1CHRM5CHKAALOX15 | |
| SCHEMBL18221640 | 0.74 | ALDH1A1 (0.52) | KDM4EMEN1KMT2AALDH1A1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174658-B | High-performance BaTiO with core-shell structure3Base ceramic dielectric material and preparation method thereof | 泗阳群鑫电子有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-118119630-A | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-116589489-A | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023061445-A1 | BORONIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-112174658-B | High-performance BaTiO with core-shell structure3Base ceramic dielectric material and preparation method thereof | 泗阳群鑫电子有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| CN-112174658-A | High-performance BaTiO with core-shell structure3Base ceramic dielectric material and preparation method thereof | 泗阳群鑫电子有限公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-1802603-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| CN-1051036-A | The treatment of HIV (human immunodeficiency virus) infections and in treatment used compound | UNIROYAL CHEM CO INC (US) | 1991-05-01 | — | — | CN | disclosed |
| US-5003069-A | Chichibabin reaction | REILLY INDUSTRIES, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0165572-A2 | Herbicidal sulfonyl urea | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-12-27 | — | — | EP | disclosed |
| EP-0098684-A2 | Modified chichibabin reaction, and novel pyridine derivatives | REILLY INDUSTRIES, INC. (US) | 1984-01-18 | — | — | EP | disclosed |
| US-4386209-A | Chichibabin reaction | REILLY TAR & CHEMICAL CORPORATION (US) | 1983-05-31 | — | — | US | disclosed |
| US-4112101-A | N-(Pyridyl)-1H-(or 2H) tetrazole-5-carboxamide derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | NOS3 1744/4885NOS2 2286/4885NOS1 3166/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | NOS3 4318/4885NOS2 4429/4885NOS1 4432/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | NOS3 2711/4885NOS2 3054/4885NOS1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.